Key factors
symEYES
exchUS
MCap54.38M
Beta2.557
EPS-0.22
Div date0000-00-00
Yesterday
symEYES
exchUS
close4.14
50 Day MA5.834
200 Day MA5.130
Target Price 2.5
Market Cap Mln54.38
Share statistics
Shares Outstanding13.13M
Shares Float9377.68K
Percent Institutions5.725
PercentInsiders28.61
SharesShort1082.86K
Short Ratio5.21
Shares Short Prior Month1132.36K
Short Percent3.849
Revenue TTM 497.0K
Revenue Per Share TTM 0.027
Quarterly Revenue Growth YOY -71.8
Gross Profit TTM 130.0K
EBITDA-9077.0K
Diluted Eps TTM-0.22
earning
Earnings Share -0.22
Dividend
Dividend Date2020-01-06
Last Split Date 2022-08-19
Last Split Factor1:3
business
Enterprise Value Ebitda 0.202
Enterprise Value Revenue85.70
Book Value /share 4.8
Price Book MRQ 0.862
Price Sales TTM 167.39
ReturnOnAssetsTTM -0.08
ReturnOnEquityTTM-0.13
Gic GroupHealth Care Equipment & Services
Gic IndustryHealth Care Equipment & Supplies
Gic Sector Health Care
Gic Sub Industry Health Care Equipment
IndustryHealth Care Equipment & Supplies
SectorHealthcare
ISIN US81362J2096
CIK 1266806
Code EYES
CUSIP 81362J209
Employer Id Number 02-0692322
CountryISO US
Currency CodeUSD
Currency Name US Dollar
Exchange NASDAQ
Currency Symbol $
Type Common Stock
UpdatedAt 2022-10-23
is Delisted 1
Delisted Date 2022-08-30
Home Category Domestic Primary
Fiscal Year End December
Full Time Employees15.0
IPODate 2014-11-19
International Domestic Domestic
MostRecent Quarter2022-06-30
Contact
NameSecond Sight Medical Products
Address13170 Telfair Avenue, Sylmar, CA, United States, 91342
Country NameUSA
Phone818 833 5000
Web URLhttps://www.secondsight.com
As of August 30, 2022, Second Sight Medical Products, Inc. was acquired by Nano Precision Medical, Inc., in a reverse merger transaction. Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.